Heidelberg Pharma AG

Earnings Release • Sep 29, 2009

News Details

Ad-hoc | 29 September 2009 17:07

WILEX AG: Preliminary data of MESUPRON(R) show impressive increase in overall survival of patients with pancreatic cancer

WILEX AG / Research Update

29.09.2009

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

Munich, 29 September 2009. The Munich-based biopharmaceutical company WILEX
AG (ISIN DE0006614720 / Frankfurt Stock Exchange / Prime Standard) today
announced preliminary data from the clinical Phase II trial with the oral
drug candidate MESUPRON(R) in combination with the chemotherapeutic agent
Gemcitabine (Gemzar(R), Eli Lilly and Company, USA) in pancreatic cancer
patients.

Patients with locally advanced, inoperable, non-metastatic pancreatic
cancer have been treated with combination therapy in the study since June
2007. The study is a randomised, open label, three-arm Phase II trial.
Patients are administered either Gemzar(R) alone or in combination with a
daily oral dose of 200 mg or 400 mg MESUPRON(R) respectively until
progression. The therapy has proven to be safe and well tolerated.

Gemzar(R) alone demonstrated a tumour response of 9.7%. Co-administration
of 200 mg MESUPRON(R) led to an increase to 22.6% and to 33.3% with 400 mg
MESUPRON(R). The one year survival with Gemzar(R) alone was 37%. This
increased to 45% with 200 mg MESUPRON(R) and to 53% with 400 mg
MESUPRON(R). The median survival of the patients improved by 30% from 10.2
months with Gemzar(R) to 13.5 months in combination with 400 mg
MESUPRON(R).

The data, which were discussed with the Medical Advisory Board, are
preliminary as only 59 of the patients enrolled in the trial have died; 72
deaths are required for the final analysis.

Contact
WILEX AG
Katja Arnold (CIRO)
Investor & Public Relations
Grillparzerstr. 10
81675 Munich
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
E-mail: investors@wilex.com

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

29.09.2009 Financial News transmitted by DGAP

---

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Deutschland
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of News DGAP News-Service

---